Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement
January 31, 2023 17:00 ET
|
Chembio Diagnostics, Inc.; Biosynex
Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide...
Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
November 28, 2022 08:00 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the...
Chembio Diagnostics Reports Third Quarter 2022 Financial Results
November 03, 2022 16:05 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases,...
Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022
October 20, 2022 16:05 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will...
Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay
September 06, 2022 08:00 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it...
Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development
August 16, 2022 08:00 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it...
Chembio Diagnostics Reports Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases,...
Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022
July 21, 2022 16:05 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will...
Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel
June 15, 2022 08:00 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., June 15, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the...
Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors
May 24, 2022 16:15 ET
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the...